Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 5/20 | 0.45 |
| ▸ | NMT2 | O60551 | 4/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27739976 | 1.00 | PTGS1 (0.46) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL27739982 | 1.00 | PTGS1 (0.46) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL29801954 | 0.96 | PTGS1 (0.43) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL30419451 | 0.96 | PTGS1 (0.43) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL29714945 | 0.96 | PTGS1 (0.43) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL29801851 | 0.93 | PTGS1 (0.43) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL29373405 | 0.92 | FOLH1 (0.52) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL30026553 | 0.91 | PTGS1 (0.42) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL29714931 | 0.91 | PTGS1 (0.42) | PTGS1GSTK1SIRT6SIRT1FOLH1 | |
| SCHEMBL29427845 | 0.91 | PTGS1 (0.42) | PTGS1GSTK1SIRT6SIRT1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| CN-119300868-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119053607-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2024-11-29 | — | — | CN | claimed |
| WO-2024193692-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | 映恩生物制药（苏州）有限公司 | 2024-09-26 | — | — | WO | claimed |
| CN-118684724-A | Linker and use thereof in ligand drug conjugates | 映恩生物制药（苏州）有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-122080121-A | Linker and use thereof in ligand drug conjugates | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4710946-A1 | MULTI-PROJECTILE ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4544047-A2 | ENGINEERED TRNA AND METHODS OF USE | The University of Chicago (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119731319-A | Engineered tRNA and methods of use thereof | 芝加哥大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119300868-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119053607-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023250446-A2 | ENGINEERED tRNA AND METHODS OF USE | THE UNIVERSITY OF CHICAGO (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115279905-A | Synthetic RIG-I like receptor agonists | 里珍纳龙药品有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220267379-A1 | NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2022-08-25 | — | — | US | disclosed |
| EP-3999530-A1 | NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-05-25 | — | — | EP | disclosed |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | Magenta Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20090215986-A1 | Solution Synthesis of Peptide Cell Growth Stimulators | EPSTEIN DAVID | 2009-08-27 | — | — | US | disclosed |
| US-20070213505-A1 | Solution Synthesis of Peptide Cell Growth Stimulators | EPSTEIN DAVID | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | PTGS1 3783/4885GSTK1 1255/4885SIRT6 2321/4885 |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | CLSPN, SDCBP, DCLRE1A | PTGS1 4086/4885GSTK1 1922/4885SIRT6 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.